Explore
Validate
Learn
Western blot
Immunocytochemistry
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA021616 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA021616, RRID:AB_1848342
- Product name
- Anti-EZR
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human EZR, Gene description: ezrin, Alternative Gene Names: VIL2, Validated applications: WB, IHC, ICC, Uniprot ID: P15311, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.2 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references The podocyte-specific knockout of palladin in mice with a 129 genetic background affects podocyte morphology and the expression of palladin interacting proteins
The Activity of KIF14, Mieap, and EZR in a New Type of the Invasive Component, Torpedo-Like Structures, Predetermines the Metastatic Potential of Breast Cancer
Incident urothelial cancer in the Malmö Diet and Cancer Study: cohort characteristics and further validation of ezrin as a prognostic biomarker.
Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts.
Dryer S, Artelt N, Ritter A, Leitermann L, Kliewe F, Schlüter R, Simm S, van den Brandt J, Endlich K, Endlich N
PLOS ONE 2021;16(12):e0260878
PLOS ONE 2021;16(12):e0260878
The Activity of KIF14, Mieap, and EZR in a New Type of the Invasive Component, Torpedo-Like Structures, Predetermines the Metastatic Potential of Breast Cancer
Gerashchenko T, Zolotaryova S, Kiselev A, Tashireva L, Novikov N, Krakhmal N, Cherdyntseva N, Zavyalova M, Perelmuter V, Denisov E
Cancers 2020;12(7):1909
Cancers 2020;12(7):1909
Incident urothelial cancer in the Malmö Diet and Cancer Study: cohort characteristics and further validation of ezrin as a prognostic biomarker.
Wennersten C, Andersson G, Boman K, Nodin B, Gaber A, Jirström K
Diagnostic pathology 2014 Oct 3;9:189
Diagnostic pathology 2014 Oct 3;9:189
Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts.
Andersson G, Wennersten C, Gaber A, Boman K, Nodin B, Uhlén M, Segersten U, Malmström PU, Jirström K
BMC urology 2014 May 12;14:36
BMC urology 2014 May 12;14:36
No comments: Submit comment
Enhanced validation
- Submitted by
- Atlas Antibodies (provider)
- Enhanced method
- Genetic validation
- Main image
- Experimental details
- Western blot analysis in U-251MG cells transfected with control siRNA, target specific siRNA probe #1 and #2, using Anti-EZR antibody. Remaining relative intensity is presented. Loading control: Anti-GAPDH.
- Sample type
- Human
- Protocol
- Protocol
Supportive validation
- Submitted by
- Atlas Antibodies (provider)
- Enhanced method
- Orthogonal validation
- Main image
- Experimental details
- Immunohistochemistry analysis in human placenta and skeletal muscle tissues using HPA021616 antibody. Corresponding EZR RNA-seq data are presented for the same tissues.
- Sample type
- Human
- Protocol
- Protocol
